FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
出版年份 2014 全文链接
标题
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
作者
关键词
Colorectal cancer, <em class=EmphasisTypeItalic >FCGR2A</em>, <em class=EmphasisTypeItalic >FCGR3A</em>, Polymorphism, Cetuximab
出版物
BMC CANCER
Volume 14, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-05-19
DOI
10.1186/1471-2407-14-340
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
- (2013) Rosa Calemma et al. Journal of Translational Medicine
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
- (2013) F V Negri et al. PHARMACOGENOMICS JOURNAL
- Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
- (2012) Javier Rodríguez et al. EUROPEAN JOURNAL OF CANCER
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
- (2012) Seong Joon Park et al. ONCOLOGY
- Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
- (2011) Laetitia Dahan et al. BMC CANCER
- Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan
- (2011) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
- (2010) K. Tamura et al. ANNALS OF ONCOLOGY
- Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
- (2010) David Paez et al. CANCER SCIENCE
- Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) againstKRAS-mutated tumor cells
- (2010) Martin Schlaeth et al. CANCER SCIENCE
- Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review
- (2010) Jolien Tol et al. CLINICAL THERAPEUTICS
- Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
- (2010) Jan Pander et al. EUROPEAN JOURNAL OF CANCER
- Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)
- (2010) Pierpaolo Correale et al. EUROPEAN JOURNAL OF CANCER
- Colorectal cancer
- (2010) David Cunningham et al. LANCET
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies
- (2009) Santiago Rodriguez et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
- (2009) Ana Paula de Souza et al. Expert Review of Anticancer Therapy
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
- (2008) G. Lurje et al. CLINICAL CANCER RESEARCH
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer
- (2008) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now